FDA approves expanded indication of Biktarvy for treatment of HIV-1 in pediatric populations – Gilead Sciences
Gilead Sciences, Inc. announced the FDA approved a new low-dose tablet dosage form of Biktarvy (bictegravir 30 mg/emtricitabine 120 mg/tenofovir alafenamide 15 mg tablets) for pediatric patients weighing… read more.